Skip to content
lifestyle.latabloid.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
argenx SE
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 6, 2026
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
August 3, 2026
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
July 27, 2026
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
July 23, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 22, 2026
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 21, 2026
argenx to Present at BofA Securities 2026 Health Care Conference
May 21, 2026
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
May 21, 2026
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
May 20, 2026
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
April 18, 2026
1
2
Next Page
→